Overview
7 featuresHeart Simulator sits in PulseGate's Medical & telehealth category. It helps medical students and professionals understand cardiac electrophysiology and ECG interpretation through interactive simulation. It is built as a consumer product for medical students and healthcare professionals. Pricing is paid, from $2.99. It ships for the web and iOS.
Behind Heart Simulator is Epicardio Ltd, based in the United States, and it first shipped in 2021. Key capabilities include 3D heart simulation, ECG visualization, and interactive tutorials. The interface is available in 5 languages, including English, German, and Spanish.
- ✓3D heart simulation
- ✓ECG visualization
- ✓Interactive tutorials
- ✓Electrophysiology parameters
- ✓Live ECG display
- ✓Simulation controls
- ✓Voice-over tutorials
Tagsecg-simulatorcardiology-educationmedical-training3d-anatomy
Built with & integrations
Trust & compliance
Verified signals✓HTTPS✓Multi-language✓Store-verified publisher
Indexing history
What PulseGate has recorded for this listing
Nothing recorded for this listing in this window.
Frequently asked questions about Heart Simulator
- What is Heart Simulator?
- Heart Simulator helps medical students and professionals understand cardiac electrophysiology and ECG interpretation through interactive simulation. It is catalogued under Medical & telehealth on PulseGate.
- Who is Heart Simulator for?
- Heart Simulator is a consumer product built for medical students and healthcare professionals.
- How much does Heart Simulator cost?
- Paid plans start at $2.99.
- What platforms does Heart Simulator run on?
- Heart Simulator runs on the web and iOS.
- Is Heart Simulator still active?
- Unverified. Heart Simulator has not been re-checked since it entered the index, so there is no finding either way — and only a positive finding would say otherwise.
- Who develops Heart Simulator?
- Heart Simulator is developed by Epicardio Ltd, based in the United States.
- How long has Heart Simulator been around?
- Heart Simulator first shipped in 2021.